Yahoo Finance | EN590 Commodities

Market Analysis · 2026-05-18T19:44:37.000Z

Regeneron Pharmaceuticals (REGN) shares tanked this morning as the biotech firm announced its highly anticipated Phase 3 trial evaluating an experimental skin cancer combination therapy failed to meet its primary endpoint. The late-stage trial REGN’s fianlimab (LAG-3 inhibitor), combined with its established immuno-therapy Libtayo, against Merck’s (MRK) blockbuster standard-of-care, Keytruda, in over 1,500 advanced melanoma patients. Dear Sandisk Stock Fans, Mark Your Calendars for May 20 Stocks Set to Open Lower as Oil Rises Amid Iran Impasse, Nvidia Earnings and Fed Minutes Awaited How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered r

About EN590 Commodities Group

25+ years in mineral exploration and extraction. 15+ years of global commodity trading. Based in New York, USA — serving 75+ countries. Products: EN590 Diesel · Crude Oil · Jet Fuel · Mazut · Bitumen · Sulphur 99.5% · Urea 46% · NPK Fertilizers.

📲 Join our Telegram channel: t.me/EN590

📰 Visit our Blog

#energy #commodities #EN590 #diesel #crudeoil #sulphur #urea #fertilizer #LNG #trading #NewYork